-+ 0.00%
-+ 0.00%
-+ 0.00%

Keymed Biosciences says China regulator grants breakthrough therapy designation for CM512 in CRSwNP

PUBT·07/23/2026 04:00:58
Listen to the news
Keymed Biosciences says China regulator grants breakthrough therapy designation for CM512 in CRSwNP
  • Keymed Biosciences’ CM512 was added to China’s NMPA CDE breakthrough therapy list for chronic rhinosinusitis with nasal polyps.
  • The TSLP/IL-13 bispecific antibody is in a randomized, double-blind, placebo-controlled Phase II trial in CRSwNP.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12253494), on July 23, 2026, and is solely responsible for the information contained therein.